Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
No abstract available

Keywords: COVID-19; SARS-CoV-2; hematology; multiple myeloma; oncology; vaccine.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antibody Formation
  • COVID-19*
  • Humans
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics
  • RNA
  • SARS-CoV-2
  • Vaccination

Substances

  • RNA